Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 66

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 66
---
 decrease is primarily due to decreased general and administrative (“G&A”) expenses and sales and marketing expenses
related to the sale of our Spryng® products.

General
and administrative (“G&A”) expenses were $2,305,548 and $2,500,378 for the six months ended September 30, 2025 and 2024,
respectively. General and administrative expenses include compensation and benefits, contracted services, legal and consulting fees,
and stock compensation expenses.

Sales
and marketing expenses were $1,408,974 and $1,154,720 for the six months ended September 30, 2025 and 2024, respectively. Sales and marketing
expenses include compensation, consulting, tradeshows, and stock compensation costs to support the sales of our Spryng® and PrecisePRP™
products.

Research
and development (“R&D”) expenses were $601,946 and $852,689 for the six months ended September 30, 2025 and 2024, respectively.
The decrease was primarily related to decreased clinical studies due to tight cash flow constraints.

 28 

Operating
Loss. As a result of the foregoing, our operating loss was $3,909,684 and $4,217,473 for the six months ended September 30, 2025
and 2024, respectively. The decrease was related to cost-cutting initiatives in general and administrative and research and development
(“R&D”) expenses.

Other
Income (Expense). Other expense was ($1,409,162) and $5,083 for the six months ended September 30, 2025 and 2024,
respectively. Other income (expense) in 2025 consisted of unrealized loss on change in derivative liabilities, loss on disposal of
assets, amortization of debt discount and interest expense. Other income (expense) in 2024 consisted of interest expense.

Net
Loss. Our net loss for the six months ended September 30, 2025 was $5,318,846 or ($0.20) per share as compared to a net loss
of $4,222,556 or ($0.22) per share for the six months ended September 30, 2024. The increase was related to the unrealized loss on
change in derivative liabilities, loss on disposal of assets, amortization of debt discount and interest expense. The weighted
average number of shares outstanding was 25,949,915 compared to